ImexpharmSTC:IMP -1.98%98 Days Payable is 24.33 as of Mar. 2026, which is 31% below its 10-year median of 35.09. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,706.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 923 Drug Manufacturers companies, Imexpharm ranks worse than 89.49% on this metric.
Imexpharm's average Accounts Payable for the
three
months ended in Mar. 2026 was ₫85,224 Mil. Imexpharm's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₫319,623 Mil.
Hence, Imexpharm's Days Payable for the
three
months ended in Mar. 2026 was 24.33.
The historical rank and industry rank for Imexpharm's Days Payable or its related term are showing as below:
STC:IMP'
s Days Payable Range Over the Past 10 Years
Min: 19.95 Med: 35.09 Max: 85.21
Current: 30.07
During the past 13 years, Imexpharm's highest Days Payable was 85.21. The lowest was 19.95. And the median was 35.09.
STC:IMP's Days Payable is ranked worse than 89.49% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs STC:IMP: 30.07
Imexpharm's Days Payable
increased
from Mar. 2025 (20.18) to Mar. 2026 (24.33).
It may suggest that Imexpharmdelayed paying its suppliers.
Imexpharm Days Payable Related Terms
Imexpharm Days Payable Historical Data
* Premium members only.
The historical data trend for Imexpharm's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imexpharm Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Imexpharm's Days Payable distribution charts can be found below:
* The bar in red indicates where Imexpharm's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Imexpharm's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imexpharm (STC:IMP) has a Days Payable of 24.33 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Imexpharm and its competitors. This is 31% below median its historical median of 35.09. Over the past decade, Imexpharm's Days Payable has ranged from 19.95 to 85.21. According to the industry distribution chart, Imexpharm ranks #826 out of 923 companies in the Drug Manufacturers industry, placing it in the top 89.5%.
Is Imexpharm's Days Payable too high?
Imexpharm's current Days Payable of 24.33 is 31% below median its 10-year median of 35.09. Over the past 10 years, this metric has ranged from a low of 19.95 to a high of 85.21. The Drug Manufacturers industry median Days Payable is 90.98. Imexpharm's value of 24.33 is 73.3% below this industry median. Based on the distribution chart, Imexpharm ranks #826 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Imexpharm ranks #826 out of 923 companies for Days Payable. This places Imexpharm in the lower half of its industry. The industry median Days Payable is 90.98. Imexpharm's value of 24.33 is 73.3% below this benchmark. Historically, Imexpharm's own Days Payable has ranged from 19.95 to 85.21 over the past decade. While the company's 10-year median is 35.09 vs. the industry median of 90.98, Imexpharm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imexpharm's current Days Payable of 24.33 is 73.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Imexpharm and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imexpharm's current Days Payable is 24.33, which is 31% below median its own 10-year median of 35.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,706.57, compared to a current price of ₫42,050.00 — trading 18.7% below its estimated fair value. The current Days Payable is 24.33, which is 31% below median its 10-year median of 35.09 and 73.3% below the Drug Manufacturers industry median of 90.98. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Days Payable is 24.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imexpharm (STC:IMP) Overvalued in 2026?
Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued.
The current stock price of ₫42,050.00 is trading 18.7% below its estimated GF Value™ of ₫51,706.57.
GuruFocus considers Imexpharm to be Modestly Undervalued.
Key valuation signals for STC:IMP:
Days Payable: 24.33 (31% below median its 10-year median of 35.09)
GF Value™: ₫51,706.57 vs. price of ₫42,050.00 (18.7% below fair value)
Industry Position: 73.3% below the Drug Manufacturers median (#826 of 923)
No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score
Get the complete analysis for STC:IMP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:IMP has been successfully added to your 
